Remote Ischemic Conditioning for Parkinson's Disease

Condition:   Parkinson's Disease Interventions:   Device: Remote ischaemic conditioning;   Other: conventional therapy Sponsor:   General Hospital of Shenyang Military Region Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Publication date: Available online 25 May 2020Source: The Lancet NeurologyAuthor(s): Bastiaan R Bloem, Emily J Henderson, E Ray Dorsey, Michael S Okun, Njideka Okubadejo, Piu Chan, John Andrejack, Sirwan K L Darweesh, Marten Munneke
Source: The Lancet Neurology - Category: Neurology Source Type: research
Publication date: Available online 26 May 2020Source: Journal of EthnopharmacologyAuthor(s): Shanshan Fan, Qingsheng Yin, Dongna Li, Jing Ma, Lili Li, Shiwei Chai, Hong Guo, Zhen Yang
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Authors: Jones MT, Strassnig MT, Harvey PD Abstract INTRODUCTION: While antipsychotics have been generally successful in treating psychosis in schizophrenia, there is a major treatment gap for negative symptoms and cognitive deficits. Given that these aspects of the disease contribute to poor functional outcomes independently of positive symptoms, treatments would have profound implications for quality of life. The 5-HT2A- receptor has been considered a potential target for interventions aimed at negative and cognitive symptoms and multiple antagonists and inverse agonists of this receptor have been tested. ARE...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research
The increasing ageing global population is causing an upsurge in ailments related to old age, primarily dementia and Alzheimer's disease, frailty, Parkinson's, and cardiovascular disease, but also a general need for general eldercare as well as active and ...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
LEO MCKINSTRY: I don't feel very heroic these days as I shuffle around with my cane. This experience reflects the fact I have developed Parkinson's disease that impairs the functioning of the body.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
AbstractDopaminergic nigrostriatal denervation and widespread intracellular α-synuclein accumulation are neuropathologic hallmarks of Parkinson’s disease (PD). A constellation of peripheral processes, including metabolic and inflammatory changes, are thought to contribute to neurodegeneration. In the present study, we sought to obtain insight into the multifaceted pathop hysiology of PD through the application of a multi-marker discovery approach. Fifty older adults aged 70+, 20 with PD and 30 age-matched controls were enrolled as part of the EXosomes in PArkiNson Disease (EXPAND) study. A panel of 68 circulati...
Source: AGE - Category: Geriatrics Source Type: research
AbstractMicroglia-mediated central nervous system (CNS) inflammation is one of the key features of various neurodegenerative diseases, including Parkinson ’s and Alzheimer’s diseases. In the last few years, a number of studies have investigated the link between neurodegenerative diseases and CNS glial cells, in particular microglia. Microglial cells are the main resident immune cells and comprise approximately 10–15% of all CNS cells. Microglia at rest regulates CNS homeostasis via phagocytic activity, by removing pathogens and cell detritus. “Resting” microglia cells transform into an activat...
Source: Neurological Sciences - Category: Neurology Source Type: research
ConclusionsCSVD and lacunes in the basal ganglia may independently contribute to gait/posture dysfunction in PD. Promoting neurovascular health may preserve some gait/posture function of PD.
Source: Neurological Sciences - Category: Neurology Source Type: research
.
Source: Expert Opinion on Drug Discovery - Category: Drugs & Pharmacology Authors: Source Type: research
AbstractThe mechanisms underlying the neuroprotective effects of hesperidin in a murine model of PD are not fully elucidated. The current study was carried out to investigate the ability of hesperidin in modulating proinflammatory cytokines, neurotrophic factors, and neuronal recovery in 6-hydroxydopamine (6-OHDA)-induced nigral dopaminergic neuronal loss. Adult male C57BL/6 mice were randomly assigned into four groups: (I) sham/vehicle, (II) sham/hesperidin, (III) 6-OHDA/vehicle, and (IV) 6-OHDA/hesperidin. Mice received a unilateral intrastriatal injection of 6-OHDA and treated with hesperidin (50  mg/kg; per oral) ...
Source: Molecular Neurobiology - Category: Neurology Source Type: research
More News: Parkinson's Disease | Research